Trial · NCT01234649
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Insulin Secretion-Sensitivity Index (IS-SI) | 84 weeks of treatment | IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET) |
| Secondary | Fasting Blood Glucose (FBG) | 84 weeks of treatment | Fasting glucose levels in LIRA-MET group compared with PL-MET group |
| Secondary | Mean Glucose During OGTT (MBG) | 84 weeks of treatment | MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group |
| Secondary | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) | 84 weeks of treatment | HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group |
| Secondary | Matsuda Insulin Sensitivity Index Derived From OGTT | 84 weeks of treatment | OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group |
| Secondary | Insulinogenic Index (IGI) /HOMA-IR | 84 weeks of treatment | IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group |
| Secondary | Absolute Body Weight | 84 weeks of treatment | Body weight in LIRA-MET group compared with PL-MET group |
| Secondary | Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline) | Change from baseline (time 0) to study end (84 weeks) | Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent. |
| Secondary | Body Mass Index (BMI) | 84 weeks of treatment | BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group |
| Secondary | Waist Circumference (WC) | 84 weeks of treatment | Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET |
| Secondary | Waist-to-Hip Ratio (WHR) | 84 weeks of treatment | Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group |
| Secondary | Waist to Height Ratio (WHtR) | 84 weeks of treatment | Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group |
| Secondary | Total Cholesterol (CHOL) Levels | 84 weeks of treatment | CHOL levels in LIRA-MET group compared with PL-MET group |
| Secondary | High Density Lipoprotein Cholesterol (HDL-C) Levels | 84 weeks of treatment | HDL-C levels in LIRA-MET group compared with PL-MET group |
| Secondary | Low Density Lipoprotein Cholesterol (LDL-C) Levels | 84 weeks of treatment | LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group |
| Secondary | Triglyceride (TRG) Levels | 84 weeks of treatment | TRG concentrations in LIRA-MET group compared with PL-MET group |
| Secondary | Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C) | 84 weeks of treatment | TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group |
| Secondary | Systolic Blood Pressure | 84 weeks of treatment | SBP in LIRA-MET group compared with PL-MET group |
| Secondary | Diastolic Blood Pressure | 84 weeks of treatment | DBP in LIRA-MET group compared with PL-MET group |
| Secondary | Alanine Aminotransferase (ALT) Levels | 84 weeks of treatment | Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01234649/registered